2017 Filing For Shionogi's Novel Flu Drug In Japan On Back Of Strong Phase III Data
Executive Summary
Shionogi is on track to file its novel flu treatment S-033188 with regulators in Japan by the end of the year on the back of positive Phase III data.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.